Tetra Bio-Pharma Inc. (JAM1.F)
Chart Events
Performance Outlook
| Previous Close | 0.0926 |
| Open | 0.0641 |
| Bid | 0.0638 x 4074100 |
| Ask | 0.0923 x 2558200 |
| Day's Range | 0.0641 - 0.0641 |
| 52 Week Range | 0.0638 - 0.3525 |
| Volume | |
| Avg. Volume | 8,048 |
| Market Cap | 30.676M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- CNW Group
Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million. The Offering was co-led by Research Capital Corporation and Echelon Wealth Partners Inc. as co-lead agents and joint bookrunners (the "Age
- GlobeNewswire
REPEAT – Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the price of its marketed public offering (the “Offering”) of units of the Company (the “Units”) previously announced on December 1, 2021. Pursuant to the Offering, the Company intends to issue Unit
- GlobeNewswire
Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the price of its marketed public offering (the “Offering”) of units of the Company (the “Units”) previously announced on December 1, 2021. Pursuant to the Offering, the Company intends to issue Unit
